Acute	acute	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
attack	attack	O	O	O	O
after	after	O	O	O	O
exposure	exposure	O	O	O	O
to	to	O	O	O	O
telithromycin	telithromycin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

INTRODUCTION	introduction	O	O	O	O
:	:	O	O	O	O
Antibiotic-associated	antibiotic-associated	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
rare	rare	O	O	O	O
.	.	O	O	O	O

With	with	O	O	O	O
widespread	widespread	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
antimicrobial	antimicrobial	O	O	O	O
agents	agents	O	O	O	O
,	,	O	O	O	O
however	however	O	O	O	O
,	,	O	O	O	O
hepatic	hepatic	O	DISEASE	OTHERS	I
injury	injury	O	DISEASE	OTHERS	I
occurs	occurs	O	O	O	O
frequently	frequently	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
among	among	O	O	O	O
adverse	adverse	O	O	OTHERS	I
drug	drug	O	O	OTHERS	I
reactions	reactions	O	O	OTHERS	I
,	,	O	O	O	O
idiosyncratic	idiosyncratic	O	O	O	O
reactions	reactions	O	O	O	O
are	are	O	O	O	O
the	the	O	O	O	O
most	most	O	O	O	O
serious	serious	O	O	O	O
.	.	O	O	O	O

CASE	case	O	O	O	O
SUMMARY	summary	O	O	O	O
:	:	O	O	O	O
A	a	O	O	O	O
25-year-old	25-year-old	O	O	O	O
male	male	O	O	O	O
patient	patient	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
height	height	O	O	O	O
of	of	O	O	O	O
175	175	O	O	O	O
cm	cm	O	DISEASE	OTHERS	I
and	and	O	O	O	O
weight	weight	O	O	O	O
of	of	O	O	O	O
72	72	O	O	O	O
kg	kg	O	O	O	O
presented	presented	O	O	O	O
to	to	O	O	O	O
Marmara	marmara	O	O	O	O
University	university	O	O	O	O
Hospital	hospital	O	O	O	O
Emergency	emergency	O	O	OTHERS	I
Department	department	O	O	OTHERS	I
,	,	O	O	O	O
Istanbul	istanbul	O	O	O	O
,	,	O	O	O	O
Turkey	turkey	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
5	5	O	O	O	O
days	days	O	O	O	O
'	'	O	O	O	O
history	history	O	O	O	O
of	of	O	O	O	O
jaundice	jaundice	O	DISEASE	OTHERS	I
,	,	O	O	O	O
malaise	malaise	O	O	OTHERS	I
,	,	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
vomiting	vomiting	O	DISEASE	OTHERS	I
.	.	O	O	O	O

He	he	O	O	O	O
had	had	O	O	O	O
been	been	O	O	O	O
prescribed	prescribed	O	O	O	O
telithromycin	telithromycin	CHEMICALS	O	OTHERS	I
400	400	O	O	O	O
mg/d	mg/d	O	O	O	O
PO	po	O	O	O	O
to	to	O	O	O	O
treat	treat	O	O	O	O
an	an	O	O	O	O
upper	upper	O	O	OTHERS	I
respiratory	respiratory	O	O	OTHERS	I
tract	tract	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
7	7	O	O	O	O
days	days	O	O	O	O
prior	prior	O	O	O	O
.	.	O	O	O	O

Admission	admission	O	O	O	O
laboratory	laboratory	O	O	O	O
tests	tests	O	O	O	O
were	were	O	O	O	O
as	as	O	O	O	O
follows	follows	O	O	O	O
:	:	O	O	O	O
alanine	alanine	CHEMICALS	O	OTHERS	I
aminotransferase	aminotransferase	O	O	O	O
,	,	O	O	O	O
67	67	O	O	O	O
U/L	u/l	O	O	O	O
(	(	O	O	O	O
reference	reference	O	O	O	O
range	range	O	O	O	O
,	,	O	O	O	O
10	10	O	O	O	O
-	-	O	O	O	O
37	37	O	O	O	O
U/L	u/l	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
aspartate	aspartate	CHEMICALS	O	OTHERS	I
aminotransferase	aminotransferase	O	O	O	O
,	,	O	O	O	O
98	98	O	O	O	O
U/L	u/l	O	O	O	O
(	(	O	O	O	O
10	10	O	O	O	O
-	-	O	O	O	O
40	40	O	O	O	O
U/L	u/l	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
alkaline	alkaline	CHEMICALS	O	OTHERS	I
phosphatase	phosphatase	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
513	513	O	O	O	O
U/L	u/l	O	O	O	O
(	(	O	O	O	O
0	0	O	O	O	O
-	-	O	O	O	O
270	270	O	O	O	O
U/L	u/l	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
gamma-glutamyltransferase	gamma-glutamyltransferase	O	O	O	O
,	,	O	O	O	O
32	32	O	O	O	O
U/L	u/l	O	O	O	O
(	(	O	O	O	O
7	7	O	O	O	O
-	-	O	O	O	O
49	49	O	O	O	O
U/L	u/l	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
amylase	amylase	O	O	O	O
,	,	O	O	O	O
46	46	O	O	O	O
U/L	u/l	O	O	O	O
(	(	O	O	O	O
0	0	O	O	O	O
-	-	O	O	O	O
220	220	O	O	O	O
U/L	u/l	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
total	total	O	O	O	O
bilirubin	bilirubin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
20.1	20.1	O	O	O	O
mg/dL	mg/dl	O	O	O	O
(	(	O	O	O	O
0.2	0.2	O	O	O	O
-	-	O	O	O	O
1.0	1.0	O	O	O	O
mg/dL	mg/dl	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
direct	direct	O	O	O	O
bilirubin	bilirubin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
14.8	14.8	O	O	O	O
mg/dL	mg/dl	O	O	O	O
(	(	O	O	O	O
0	0	O	O	O	O
-	-	O	O	O	O
0.3	0.3	O	O	O	O
mg/dL	mg/dl	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
and	and	O	O	O	O
albumin	albumin	O	O	O	O
,	,	O	O	O	O
4.7	4.7	O	O	O	O
mg/dL	mg/dl	O	O	O	O
(	(	O	O	O	O
3.5	3.5	O	O	O	O
-	-	O	O	O	O
5.4	5.4	O	O	O	O
mg/dL	mg/dl	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
toxin	toxin	O	O	O	O
,	,	O	O	O	O
alcohol	alcohol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
other	other	O	O	O	O
drugs	drugs	O	O	O	O
were	were	O	O	O	O
reported	reported	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
had	had	O	O	O	O
suffered	suffered	O	O	O	O
a	a	O	O	O	O
previous	previous	O	O	O	O
episode	episode	O	O	O	O
of	of	O	O	O	O
"	"	O	O	O	O
acute	acute	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
of	of	O	O	O	O
unknown	unknown	O	O	O	O
origin	origin	O	O	O	O
,	,	O	O	O	O
"	"	O	O	O	O
that	that	O	O	O	O
occurred	occurred	O	O	O	O
after	after	O	O	O	O
telithromycin	telithromycin	CHEMICALS	O	OTHERS	I
usage	usage	O	O	O	O
.	.	O	O	O	O

Both	both	O	O	O	O
incidents	incidents	O	O	O	O
occurred	occurred	O	O	O	O
within	within	O	O	O	O
a	a	O	O	O	O
year	year	O	O	O	O
.	.	O	O	O	O

DISCUSSION	discussion	O	O	O	O
:	:	O	O	O	O
Telithromycin	telithromycin	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
ketolide	ketolide	O	O	O	O
antibacterials	antibacterials	O	O	O	O
to	to	O	O	O	O
receive	receive	O	O	O	O
US	us	O	O	O	O
Food	food	O	O	O	O
and	and	O	O	O	O
Drug	drug	O	O	O	O
Administration	administration	O	O	O	O
approval	approval	O	O	O	O
for	for	O	O	O	O
clinical	clinical	O	O	O	O
use	use	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
infrequent	infrequent	O	O	O	O
and	and	O	O	O	O
usually	usually	O	O	O	O
reversible	reversible	O	O	O	O
severe	severe	O	O	O	O
hepatic	hepatic	O	O	OTHERS	I
dysfunction	dysfunction	O	O	OTHERS	I
.	.	O	O	O	O

Based	based	O	O	O	O
on	on	O	O	O	O
a	a	O	O	O	O
score	score	O	O	O	O
of	of	O	O	O	O
8	8	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
Naranjo	naranjo	O	O	O	O
adverse	adverse	O	O	OTHERS	I
drug	drug	O	O	OTHERS	I
reaction	reaction	O	O	OTHERS	I
probability	probability	O	O	O	O
scale	scale	O	O	O	O
,	,	O	O	O	O
telithromycin	telithromycin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
the	the	O	O	O	O
probable	probable	O	O	O	O
cause	cause	O	O	O	O
of	of	O	O	O	O
acute	acute	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
in	in	O	O	O	O
this	this	O	O	O	O
patient	patient	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
pathological	pathological	O	O	O	O
findings	findings	O	O	O	O
suggested	suggested	O	O	O	O
drug-induced	drug-induced	O	O	O	O
toxic	toxic	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Recurrence	recurrence	O	O	O	O
of	of	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
attack	attack	O	O	O	O
might	might	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
avoided	avoided	O	O	O	O
if	if	O	O	O	O
the	the	O	O	O	O
initial	initial	O	O	O	O
incident	incident	O	O	O	O
had	had	O	O	O	O
been	been	O	O	O	O
communicated	communicated	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
attending	attending	O	O	O	O
physician	physician	O	O	O	O
who	who	O	O	O	O
prescribed	prescribed	O	O	O	O
telithromycin	telithromycin	CHEMICALS	O	OTHERS	I
the	the	O	O	O	O
second	second	O	O	O	O
time	time	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
Here	here	O	O	O	O
we	we	O	O	O	O
report	report	O	O	O	O
a	a	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
acute	acute	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
probably	probably	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
telithromycin	telithromycin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

